8-K: Artiva AlloNK Shows Positive Safety, B-Cell Depletion in Autoimmune Trials

Artiva Biotherapeutics announced positive initial safety and translational data for AlloNK in autoimmune diseases, demonstrating deep B-cell depletion and good tolerability in outpatient settings.

Summary

• Positive initial safety and translational data for AlloNK (AB-101) in combination with rituximab or obinutuzumab for autoimmune diseases were reported.
• 32 patients with refractory RA, Sjögren's disease, idiopathic inflammatory myopathies, systemic sclerosis, and SLE/lupus nephritis were treated as of the October 1, 2025 data cutoff.
• Patients received either 1 billion or 4 billion AlloNK cells per dose, administered as outpatients, primarily at community rheumatology sites without specialized oncology oversight, demonstrating feasibility in this setting.
• The treatment regimen was generally well tolerated; most treatment-emergent adverse events (TEAEs) were Grade 1 or 2, transient, and consistent with expected effects of cyclophosphamide (Cy) and fludarabine (Flu) conditioning.
• No AlloNK-related Grade 3+ TEAEs, serious adverse events, discontinuations, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), Graft-versus-Host Disease, or hypogammaglobulinemia were reported.
• Only one patient was hospitalized for an adverse event, a skin infection unrelated to AlloNK, within 28 days post-treatment.
• All 23 patients with samples analyzed demonstrated non-quantifiable peripheral CD19+ B-cell levels by Day 13 of treatment, irrespective of baseline B-cell counts, confirmed by high-sensitivity assays.
• B-cell reconstitutions in four patients treated with AlloNK + rituximab showed predominantly naive and transitional cells, consistent with CD19-auto-CAR-T treatment observations.
• The depth and consistency of B-cell depletion are comparable to CD19-auto-CAR-T cell therapies and meaningfully greater than rituximab alone, as reported in published studies.
• There is a significant unmet need for over 150,000 U.S. patients with refractory RA who have failed at least two biologic or targeted synthetic disease modifying anti-rheumatic drugs (b/ts DMARDs), where current ACR50 response rates are 10-20%.

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive initial clinical data for AlloNK, highlighting excellent safety, strong B-cell depletion comparable to advanced cell therapies, and feasibility of outpatient administration. This addresses a significant unmet medical need and sets the stage for pivotal trials, indicating strong progress and potential for the company's lead candidate.

Positives

• AlloNK treatment regimen was generally well tolerated in autoimmune patients, with most TEAEs being Grade 1 or 2 and transient.
• No AlloNK-related Grade 3+ TEAEs or serious adverse events were reported.
• No discontinuations, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), Graft-versus-Host Disease, or hypogammaglobulinemia were observed.
• The feasibility of AlloNK administration and patient management in outpatient and community rheumatology settings without specialized oncology oversight was demonstrated.
• Consistent and complete B-cell depletion was observed in all 23 analyzed patients by Day 13, supporting the intended mechanism of action.
• The depth and consistency of B-cell depletion are comparable to CD19-auto-CAR-T cell therapies and meaningfully greater than rituximab alone.
• AlloNK addresses a significant unmet need in refractory rheumatoid arthritis, a condition affecting over 150,000 patients in the U.S. with limited effective treatment options.

Risks

• Statements in this report that are not historical facts are forward-looking statements and are subject to known and unknown risks and uncertainties, meaning actual events or circumstances may not occur as expected.
• Factors that may cause actual results to differ from current expectations are discussed in the Company's filings with the SEC, including the 'Risk Factors' section in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
• AlloNK is an investigational compound and is not approved for marketing by the FDA or any other regulatory authority.

Future Outlook

Artiva plans to share initial clinical response data from over 15 refractory RA patients, some with 6 months or more follow-up, in the first half of 2026. The company also intends to conduct FDA regulatory interactions in the first half of 2026 to align on a potential pivotal trial design for AlloNK in refractory RA, with the goal of being the first agent in the deep B-cell depleting field to initiate such a trial. Management believes AlloNK has the potential to drive deep B-cell depletion with a high rate of durable responses and a tolerability profile compatible with community administration, making it applicable to various autoimmune disease indications.

Management Comments

• "Our treatment regimen has the potential to drive deep B-cell depletion with a high rate of durable responses, with a tolerability profile highly compatible with community administration, based on this initial data." Fred Aslan, M.D., President and Chief Executive Officer of Artiva Biotherapeutics.
• "We believe the deep B-cell depletion field has the potential to impact every indication in autoimmune disease, and Artiva is leading with RA, the autoimmune disease with the largest number of patients refractory to standard of care." Fred Aslan, M.D., President and Chief Executive Officer of Artiva Biotherapeutics.
• "We believe AlloNK could be the first agent in the deep B-cell depleting field to potentially start a global pivotal trial in refractory RA following our planned interactions with FDA in the first half of 2026." Fred Aslan, M.D., President and Chief Executive Officer of Artiva Biotherapeutics.
• "It is remarkable to see such consistent B-cell depletion, particularly using a high-sensitivity assay, and favorable safety and tolerability in this first clinical data readout of AlloNK in autoimmune disease." Subhashis Banerjee, M.D., Chief Medical Officer of Artiva Biotherapeutics.
• "The AlloNK treatment regimen, which includes Cy / Flu, has been generally well tolerated in autoimmune patients. There were no CRS or ICANS events and a low infection rate reported. We believe this supports administration in outpatient and community rheumatology settings." Subhashis Banerjee, M.D., Chief Medical Officer of Artiva Biotherapeutics.

Industry Context

This announcement positions AlloNK as a promising candidate in the evolving landscape of autoimmune disease treatment, particularly in the 'deep B-cell depleting field.' The ability to achieve B-cell depletion comparable to CD19-auto-CAR-T therapies, but with a more favorable safety profile and the critical advantage of outpatient administration, could significantly differentiate AlloNK. This addresses a major barrier to access and convenience for patients and healthcare systems, potentially making it a highly competitive option for refractory autoimmune conditions like RA, where current treatments offer limited efficacy for a substantial patient population.

Comparison to Industry Standards

• The depth and consistency of B-cell depletion achieved with AlloNK are comparable to those observed with CD19-auto-CAR-T cell therapies.
• AlloNK's B-cell depletion is meaningfully greater than that achieved with rituximab alone, as reported in published studies.
• The emerging tolerability profile of AlloNK is consistent with the treatment journey typically observed with intravenous monoclonal antibody (mAb) therapies.
• For patients with refractory RA who have failed at least two b/ts DMARDs, real-world registry data for approved agents show only a 10-20% ACR50 response, indicating a significant opportunity for AlloNK to improve upon existing standards.

Stakeholder Impact

• Shareholders: Likely positive impact due to promising clinical data, reduced program risk, and a clear path towards pivotal trials, potentially increasing company valuation.
• Patients: Potential for a new, effective, and more accessible treatment option for severe autoimmune diseases, particularly refractory RA, with a favorable safety profile and outpatient administration.
• Physicians: The demonstrated feasibility of outpatient administration in community rheumatology settings could simplify treatment logistics and expand access for patients, making AlloNK an attractive therapeutic option.
• Regulatory Authorities: The positive safety and efficacy data, coupled with planned FDA interactions, indicate significant progress towards potential market approval for a novel cell therapy.

Next Steps

• Share initial clinical response data across dose levels from more than 15 refractory RA patients, several with 6 months or more follow-up, in the first half of 2026.
• Conduct FDA regulatory interactions in the first half of 2026 to align on a potential pivotal trial design for AlloNK in refractory RA.
• Host a webcast on November 12, 2025, at 8:00 a.m. E.T. to discuss the initial safety and translational data for AlloNK and the unmet need in refractory RA.

Key Dates

Recommendation

The initial safety and translational data for AlloNK are exceptionally strong, demonstrating deep B-cell depletion comparable to CAR-T therapies but with a significantly better safety profile and the crucial advantage of outpatient administration. This addresses a major unmet need in refractory autoimmune diseases like RA. The clear path to pivotal trials and FDA interactions in H1 2026, combined with the potential to be a first-in-class agent in this space, suggests substantial upside potential. The low rate of adverse events and lack of serious complications further de-risk the program. This data significantly enhances the probability of AlloNK's clinical and commercial success.

Keywords

Artiva Biotherapeutics, AlloNK, AB-101, autoimmune disease, rheumatoid arthritis, B-cell depletion, NK cell therapy, clinical trials, safety data, translational data, outpatient treatment, refractory RA, Sjögren's disease, systemic lupus erythematosus, biotechnology, cell therapy